Fibrinogen to be a laboratory screening biomarker for polycystic ovary syndrome （PCOS） patients： a Meta-analysis

Objective To assess the fibrinogen levels in polycystic ovary syndrome （PCOS） patients and to fgure out the potential of fibrinogen to be an early phase laboratory biomarker for PCOS diagnosis. Methods A systemic literature research was performed from databases of Medline via OVID, PubMed, Web of Kn...

Full description

Saved in:
Bibliographic Details
Published in生殖与避孕：英文版 no. 2; pp. 91 - 101
Main Author Xin JI Bin ZHANG Chun-mei YING
Format Journal Article
LanguageEnglish
Published 2015
Subjects
MEDLINE数据库
Meta分析
多囊卵巢综合征
实验室
患者
生物标志物
筛查
纤维蛋白原
Online AccessGet full text

Cover

More Information
Summary:Objective To assess the fibrinogen levels in polycystic ovary syndrome （PCOS） patients and to fgure out the potential of fibrinogen to be an early phase laboratory biomarker for PCOS diagnosis. Methods A systemic literature research was performed from databases of Medline via OVID, PubMed, Web of Knowledge and the Cochrane library databases, etc. Fifteen studies including 694 PCOS patients and 548 normal controls were selected after quality assessment. Data of fibrinogen levels, age and body weight were extracted and analyzed systemically. Results Fibrinogen increases in PCOS patients with regard to data poolings of overall studies （mean difference=21.51, 95%CI=3.78-39.25, P=0.02）, National Institutes of Health （NIH）-based studies （mean difference=8. 50, 95%CI=0.91-16. 09, P= 0. 03） and Rotterdam-based studies （mean difference=45.61, 95%CI=12.18-79.03, P=0.007） respectively. PCOS patients are younger （mean difference= -2.15, 95%CI= -3.65 - -0. 64, P=0. 005） and with heavier body weight （mean difference=0.92, 95%CI=0.59- 1.25, P〈0.001） than normal controls. Conclusions Increasing in PCOS patients, fibrinogen might be used as a diagnosis biomarker for PCOS, especially in the population with younger age and heavier body weight, which indicates that fibrinogen might be used as an early phase laboratory screening biomarker in clinical practice.
Bibliography:31-1555/R
Objective To assess the fibrinogen levels in polycystic ovary syndrome （PCOS） patients and to fgure out the potential of fibrinogen to be an early phase laboratory biomarker for PCOS diagnosis. Methods A systemic literature research was performed from databases of Medline via OVID, PubMed, Web of Knowledge and the Cochrane library databases, etc. Fifteen studies including 694 PCOS patients and 548 normal controls were selected after quality assessment. Data of fibrinogen levels, age and body weight were extracted and analyzed systemically. Results Fibrinogen increases in PCOS patients with regard to data poolings of overall studies （mean difference=21.51, 95%CI=3.78-39.25, P=0.02）, National Institutes of Health （NIH）-based studies （mean difference=8. 50, 95%CI=0.91-16. 09, P= 0. 03） and Rotterdam-based studies （mean difference=45.61, 95%CI=12.18-79.03, P=0.007） respectively. PCOS patients are younger （mean difference= -2.15, 95%CI= -3.65 - -0. 64, P=0. 005） and with heavier body weight （mean difference=0.92, 95%CI=0.59- 1.25, P〈0.001） than normal controls. Conclusions Increasing in PCOS patients, fibrinogen might be used as a diagnosis biomarker for PCOS, especially in the population with younger age and heavier body weight, which indicates that fibrinogen might be used as an early phase laboratory screening biomarker in clinical practice.
fibrinogen; polycystic ovary syndrome （PCOS）; diagnosis
ISSN:1001-7844